Titles
- Feasibility and early feasibility clinical studies for certain medical devices intended to therapeutically improve glycemic control in patients with Type 2 Diabetes Mellitus: guidance for industry and Food and Drug Administration staff1
- Federal Employees Health Benefits Program: Additional monitoring mechanisms and fraud risk assessment needed to better ensure member eligibility : report to congressional requesters1
- Federal Medicaid policy1
- Federal economic stimulus projected to cut poverty in 2021, though poverty may rise as benefits expire1
- Federal efforts to address racial and ethnic disparities in Alzheimer’s disease and related dementias1
- Federal prisons: monitoring efforts to implement COVID-19 recommendations and examining first step act implementation : testimony before the Subcommittee on Crime, Terrorism, and Homeland Security, Committee on the Judiciary, House of Representatives1
- Final evaluation of California’s Whole Person Care (WPC) program1
- Financially sustaining the academic enterprise1
- Findings from the first year of Medicaid managed care in North Carolina1
- Flexibilities in controlled substances prescribing and dispensing during the COVID-19 pandemic1
- Food insecurity in familes with children1
- Food insecurity in rural, suburban, and urban New York1
- Food insecurity trended upward in midst of high inflation and fewer supports: findings from the Health Reform Monitoring Survey, June 20221
- For Medicaid-enrolled children diagnosed with lead toxicity in five states, documentation reviewed for diagnoses and treatment services raises concerns1
- Formal meetings between FDA and ANDA applicants of complex products under GDUFA: guidance for industry1
- Free preventive services improve access to care1
- From ideation to standard practice: scaling innovations in long-term services and supports1
- Funding and insurance1
- Gene therapy for hemophilia B and an update on gene therapy for hemophilia A: effectiveness and value : final evidence report1
- General clinical pharmacology considerations for neonatal studies for drugs and biological products1